Baxter To Pay Up To $330M To Buy ApaTech
The companies said Monday that Baxter will pay $240 million cash for the company. Illinois-based Baxter also may make additional payments of up to $90 million if certain sales milestones are achieved.
The deal allows Baxter to acquire ApaTech's Actifuse product, a silicate substituted calcium phosphate synthetic bone graft material...
To view the full article, register now.